Stockscreener 앱 받기
3.01
3.22%
-0.10
시장 영업 전:
3.04
0.03
+1.00%
전일 마감가:
$3.11
열려 있는:
$3.095
하루 거래량:
13.93M
Relative Volume:
1.01
시가총액:
$1.60B
수익:
$66.41M
순이익/손실:
$-559.78M
주가수익비율:
-2.5037
EPS:
-1.2022
순현금흐름:
$-328.09M
1주 성능:
+2.73%
1개월 성능:
-19.30%
6개월 성능:
-27.82%
1년 성능:
-27.38%
1일 변동 폭
$2.98
$3.17
1주일 범위
$2.77
$3.17
52주 변동 폭
$2.77
$7.18
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.01 | 1.65B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? - The Globe and Mail
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? - The Motley Fool
Recursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory? - Insider Monkey
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth Prospects - Yahoo Finance
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Morgan Stanley Raises its Price Target on Recursion (RXRX) - Insider Monkey
8 Most Oversold AI Stocks to Buy According to Analysts - Insider Monkey
RXRX (NASDAQ) Form 144: 40,000 Class A shares proposed sale via Fidelity - Stock Titan
Can Altitude Lab’s Early Wins Reframe Recursion Pharmaceuticals’ (RXRX) High-Burn Platform Bet? - Sahm
Recursion Pharmaceuticals (RXRX) price target decreased by 10.64% to 6.12 - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Initiatives - Quiver Quantitative
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Hallett David - Moomoo
Recursion (NASDAQ: RXRX) CSO RSU tax withholding on 26,657 shares - Stock Titan
Recursion (NASDAQ: RXRX) CEO has 62,701 shares withheld for RSU taxes - Stock Titan
Recursion Pharmaceuticals (RXRX) CFO reports tax-related share withholding - Stock Titan
22,821 RXRX shares withheld for taxes as Recursion director reports RSU event - Stock Titan
Recursion Pharmaceuticals, Inc.Class A Common Stock (NQ: RXRX - The Chronicle-Journal
Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News - TechStock²
Recursion Pharmaceuticals stock hits 52-week low at $2.79 - Investing.com India
Recursion Pharmaceuticals stock hits 52-week low at $2.79 By Investing.com - Investing.com Canada
RXRX Stock Price and Chart — NASDAQ:RXRX - TradingView
Q4 Earnings Estimate for RXRX Issued By KeyCorp - MarketBeat
Nvidia’s expanding role in AI-driven drug discovery, clinical research could fuel growth, says Goldman Sachs - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
RXRX Stock Price, Quote & Chart | RECURSION PHARMACEUTICALS-A (NASDAQ:RXRX) - ChartMill
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now - Insider Monkey
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.5 - Moomoo
Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5.50 From $5, Keeps Equalweight Rating - marketscreener.com
Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026 - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America Securities - The Globe and Mail
Recursion Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $6.64, Implies 118% Upside - TradingView
Recursion Pharmaceuticals (RXRX) stock dips while market gains: Key facts - MSN
Recursion Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-05-13 - Seeking Alpha
5 Unrivaled Penny Stocks to Buy Now - Insider Monkey
Recursion Q1 2026 slides: AI pipeline advances amid revenue challenges - Investing.com
State Street (RXRX) discloses 28.49M-share, 5.5% stake in Recursion - Stock Titan
4 top AI stocks to hold for a decade | 2026-05-12 | Investing News - Stockhouse
Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks - simplywall.st
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Recent Clinical And Cost Management Updates - Sahm
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M - MSN
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA Discussions - Yahoo Finance
Recursion Pharmaceuticals director Christopher Gibson sells $134,800 By Investing.com - Investing.com Australia
Recursion Pharmaceuticals director Christopher Gibson sells $134,800 - Investing.com
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리커젼 파마 주식 (RXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Director |
May 07 '26 |
Sale |
3.37 |
40,000 |
134,800 |
926,556 |
| Borgeson Blake | Director |
May 05 '26 |
Sale |
3.52 |
30,000 |
105,600 |
6,199,863 |
2.98%
1.33%
자본화:
|
볼륨(24시간):